↓ Skip to main content

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, February 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

patent
1 patent

Citations

dimensions_citation
157 Dimensions

Readers on

mendeley
85 Mendeley
Title
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
Published in
Cancer Chemotherapy and Pharmacology, February 2013
DOI 10.1007/s00280-013-2113-1
Pubmed ID
Authors

Ruth Plummer, Paul Lorigan, Neil Steven, Lucy Scott, Mark R. Middleton, Richard H. Wilson, Evan Mulligan, Nicola Curtin, Diane Wang, Raz Dewji, Antonello Abbattista, Jorge Gallo, Hilary Calvert

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Unknown 84 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 22 26%
Student > Master 12 14%
Other 10 12%
Researcher 10 12%
Student > Bachelor 9 11%
Other 14 16%
Unknown 8 9%
Readers by discipline Count As %
Medicine and Dentistry 27 32%
Biochemistry, Genetics and Molecular Biology 16 19%
Agricultural and Biological Sciences 9 11%
Chemistry 9 11%
Pharmacology, Toxicology and Pharmaceutical Science 8 9%
Other 4 5%
Unknown 12 14%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2018.
All research outputs
#7,856,604
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#688
of 2,501 outputs
Outputs of similar age
#65,783
of 195,117 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#14
of 38 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 195,117 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.